The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus?

Based on our Pharmacor Hepatitis C Virus advisory service, Decision Resources is offering an exclusive analyst call entitled The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus? Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Based on impressive clinical trial outcomes, the U.S. Food and Drug Administration (FDA) has approved the first two HCV-specific protease inhibitors, Merck/Roche's Victrelis and Vertex/Johnson & Johnson/Tanabe Pharma's Incivek. During the FDA Antiviral Drugs Advisory Committee meetings in April, many attendees remarked that “the future of HCV treatment is now” as Victrelis and Incivek represent a major advancement in the treatment of chronic HCV. Decision Resources forecasts that these novel medicines will be rapidly adopted by clinicians for treatment of chronic HCV, especially in patients who have failed to eradicate the virus with currently available therapies.

Since Victrelis and Incivek must be used in combination with the existing standard-of-care, pegylated-interferon and ribavirin, Decision Resources forecasts that the near-term market for pegylated-interferon and ribavirin will rapidly expand, owing to the uptake of Victrelis and Incivek. Additionally, although Victrelis and Incivek are expected to face competition from emerging therapies, agents that are currently in development may be subjected to more stringent regulatory hurdles on the road to marketing approval.

This 15-minute analyst call, presented by Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D., will answer the following questions:

• What was the advisory committee's assessment of Victrelis and Incivek, and how will these agents be used for treatment of chronic HCV?
• How will Roche's plan to market Victrelis in combination with its market leading interferon-alfa, Pegasys, impact the HCV drug market?
• Will follow-on HCV therapeutics face stricter regulatory scrutiny?
• Through 2019, which HCV agents are expected to launch and how will they compete against Victrelis and Incivek?

Dr. Levine-Wilkinson will conduct a live Q & A session after the presentation.

Learn more!

The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus?

June 2, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 8 New England Executive Park • Burlington, MA 01803

You are receiving this email because you have previously requested information from Decision Resources. If you wish to change your email preferences please click here.

© 2011 Decision Resources, LLC. All rights reserved.